ArticleJournal of thrombosis and haemostasis : JTH2021
Pulmonary embolism at autopsy in cancer patients.
Article in Journal of thrombosis and haemostasis : JTH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Burden and distribution of venous thromboembolism across cancer types and stages: a meta-analysis of observational studies.Frontiers in oncology · 2025Pooled it
- Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid Cancer.Circulation. Genomic and precision medicine · 2026Article
- Pulmonary origin and risk assessment of cancer-associated thrombosis.Thrombosis journal · 2026Review
- Thromboembolic disease and hemostatic alterations in tumor-bearing dogs - A narrative review.Frontiers in veterinary science · 2026Review
- Development and validation of an interpretable machine learning model for venous thromboembolism risk prediction in patients with lung cancer: a real-world study.Frontiers in medicine · 2026Article
- Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life.Nature medicine · 2025Observational
- Primary and secondary metastatic dissemination: multiple routes to cancer-related death.Molecular cancer · 2025Review
- Developing a deep learning-based imaging diagnostic framework, PVDNet, for differentiating pulmonary artery sarcoma and pulmonary thromboembolism: a multi-center observational study.The Lancet regional health. Western Pacific · 2025Article
- Article
- Contribution of an Artificial Intelligence Tool in the Detection of Incidental Pulmonary Embolism on Oncology Assessment Scans.Life (Basel, Switzerland) · 2024Article
- Renal function-adapted D-dimer cutoffs in combination with a clinical prediction rule to exclude pulmonary embolism in patients presenting to the emergency department.Internal and emergency medicine · 2024Observational
- Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study.The Lancet regional health. Europe · 2023Article
- Crosstalk between Circulating Tumor Cells and Plasma Proteins-Impact on Coagulation and Anticoagulation.Cancers · 2023Review
- Article
- Risk factors for patients with acute hospital-acquired symptomatic pulmonary thromboembolism.Scientific reports · 2023Article
- Efficacy and Safety of Anticoagulant Therapy in COVID-19-Related Pulmonary Embolism with Different Extension.Biomedicines · 2023Article
- Circulating Tumor Cells and Cancer-Associated Venous Thrombosis: A Missing Link.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Oncogenes and cancer associated thrombosis: what can we learn from single cell genomics about risks and mechanisms?Frontiers in medicine · 2023Review
- The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.Journal of thrombosis and haemostasis : JTH · 2022Article
- Pulmonary Embolism in the Cancer Associated Thrombosis Landscape.Journal of clinical medicine · 2022Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary embolism (PE) is a potentially fatal disease, but data on the incidence of fatal PE in cancer patients are scant.
objectiveWe sought to estimate the proportion of cancer patients with PE at autopsy.
methodsFor this retrospective cohort study, all autopsy reports of cancer patients were retrieved from PALGA: Dutch Pathology Registry and used for data extraction. The primary outcome was PE at time of autopsy, defined as any clot obstructing a pulmonary artery. The secondary outcome was venous thromboembolism, defined as the composite of thrombotic PE, deep vein thrombosis, splanchnic vein thrombosis, or internal jugular vein thrombosis.
resultsA total of 9571 cancer patients were included. In 1191 (12.4%; 95% confidence interval [CI], 11.8-13.1) patients, one or more PE events were observed at autopsy, of whom 1074 (90.2%) had a thrombotic embolism, 168 (14.1%) a tumor embolism, 9 (0.8%) a septic embolism, 7 (0.6%) a fat tissue embolism, and 3 (0.3%) a bone marrow embolism. Among patients with PE for whom the cause of death was specified in the autopsy report, death was considered PE-related in 642 patients (66.7%), which was 6.7% of the total study population. Venous thromboembolism was observed in 1223 (12.8%; 95% CI, 12.1-13.5) patients.
conclusionThe proportion of PE in cancer patients at autopsy is substantial. Although the study population is not representative for the total cancer population, it suggests that PE is an important disease complication in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.